Promising Small Cap Stocks To Keep An Eye On – October 17th

D. Boral ARC Acquisition I, AltC Acquisition, Sarepta Therapeutics, SolarEdge Technologies, and Spring Valley Acquisition are the five Small Cap stocks to watch today, according to MarketBeat’s stock screener tool. Small-cap stocks are shares of companies with relatively small market capitalizations, typically ranking below large- and mid-cap companies by total market value. They may offer significant growth potential, but they generally involve greater volatility and investment risk because smaller companies often have fewer resources, less-established operations, and lower trading liquidity. These companies had the highest dollar trading volume of any Small Cap stocks within the last several days.

D. Boral ARC Acquisition I (XLAB)

We are a blank check company incorporated on March 20, 2025 as a BVI business company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, which we refer to throughout this prospectus as our initial business combination.

AltC Acquisition (ALCC)

AltC Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was formerly known as Churchill Capital Corp VIII and changed its name to AltC Acquisition Corp.

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

SolarEdge Technologies (SEDG)

SolarEdge Technologies, Inc., together with its subsidiaries, designs, develops, manufactures, and sells direct current (DC) optimized inverter systems for solar photovoltaic (PV) installations in the United States, Germany, the Netherlands, Italy, rest of Europe, and internationally. It operates in two segments, Solar and Energy Storage.

Spring Valley Acquisition (SV)